Pediatric Dermatology

In this episode, Vikash Oza, MD, and James Treat, MD, discuss their SPD 2024 session (debate) revolving around the topic: Does food trigger eczema?

Nnena Agim, MD, presented a comprehensive update on non-steroidal topical therapies, highlighting off-label uses and recent FDA approvals in a session at the SPD's annual meeting.

Andrea Zaenglein, MD, discussed the role of patient counseling and addressing "hormone phobia" in young patients treated with hormonal therapies for acne in her SPD 2024 session.

Swanson discusses her SPD 2024 non-CME talk, expanding topical options for young patients, and more.

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Paller discusses her SPD 2024 lecture, "Updates from ISSVA, ESPD, and SID: What You Missed that Could Change Your Practice."

Marissa Joseph, MD, discussed inflammatory hair disorders in young children, such as CCCA, in a presentation at the SPD's annual meeting.

Lio discusses his SPD 2024 non-CME talk, new and exciting innovations in pediatric atopic dermatitis, and more.

Lisa Weibel, MD, delved into skin signs of systemic diseases in the first of 2 Hurwitz lectures to be presented at the SPD's annual meeting.

Use of WoundSeal yielded no observed complications such as infection or bleeding, according to a poster presented at the SPD's annual meeting.

Hypertension and hyperlipidemia are common among obese pediatric patients with hidradenitis suppurativa, according to a poster presented at the SPD's annual meeting.

All domains of the DLQI and CDLQI experienced improvements through 108 weeks, according to a poster presented at the SPD's annual meeting.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Julapalli discusses her SPD 2024 lecture, "Rediscovering Joy in our Lives and the Workplace," excitement for the future of pediatric dermatology, and more.

The average pain score reported during treatment was 0.4/10, according to a poster presented at the SPD's annual meeting.

Mancini discusses his SPD 2024 lecture, emphasizing off-label treatments, surrogate diagnostic markers, simpler therapies, and the importance of empathy and education.

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

In a comparison of pediatric dermatologists versus AI, dermatologists primarily exhibited greater performance.

Researchers shared details of a noninvasive technique that detects abnormal inflammatory cytokine profiles in the skin of asymptomatic infant patients who subsequently develop AD.

The recommendations were recently published in JAMA Dermatology following an extensive literature review, article grading, and a review of research questions.

Swanson shared updates and a look ahead at what is in store for pediatric dermatology.

Burnett recently spoke with Dermatology Times to discuss the background, methods, and findings of the late-breaking INTEGUMENT-PED data, as well as its potential real-world and clinical implications.

Eichenfield discusses the late-breaking data on roflumilast cream 0.05% in the pediatric patient population and its implications.

April W. Armstrong, MD, MPH, shared treatment insights with attendees at the 36th Annual Pre-AAD Meeting of the Society for Pediatric Dermatology.

Kelly M. Cordoro, MD, shared tips on implementing shared decision making in pediatric dermatology dermatology atat annual conference.

Researchers Eric Sanfilippo, BS; Leslie Castelo-Soccio MD, PhD; and Anna Yasmine Kirkorian, MD, discussed the ethical considerations and methods of removal of unwanted hair in young patients.

Maternal mental health conditions are associated with the majority of atopic diseases, according to a study.

In an interview with Dermatology Times, the executive director of Pediatric Dermatology Research Alliance (PeDRA) discusses the group's growth since 2012 and what it can offer practicing dermatologists, researchers, students, and patients.

A look into the effectiveness of dupilumab on patients aged 6-11 with severe AD shows promising results.

Researchers explored the efficacy of a multistep treatment strategy in a younger patient population.